Literature DB >> 20053404

Do genome-wide association scans provide additional information on the variation of plasma adiponectin concentrations?

G M Dallinga-Thie1, R P F Dullaart.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20053404     DOI: 10.1016/j.atherosclerosis.2009.12.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  6 in total

1.  Insulin resistance and adipokine levels correlate with early atherosclerosis - a study in prediabetic patients.

Authors:  Bogdan Mircea Mihai; Antoniu Octavian Petriş; Didona Anca Ungureanu; Cristina Mihaela Lăcătuşu
Journal:  Open Med (Wars)       Date:  2014-09-26

2.  Increased leptin/adiponectin ratio relates to low-normal thyroid function in metabolic syndrome.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Lipids Health Dis       Date:  2017-01-11       Impact factor: 3.876

3.  Relation of Serum Leptin and Adiponectin Level to Serum C-Reactive Protein: The INTERLIPID Study.

Authors:  Yasuyuki Nakamura; Hirotsugu Ueshima; Nagako Okuda; Katsuyuki Miura; Yoshikuni Kita; Tomonori Okamura; Akira Okayama; Sohel R Choudhury; Beatriz Rodriguez; Kamal H Masaki; Jeremiah Stamler
Journal:  Int J Vasc Med       Date:  2013-11-24

Review 4.  Adiponectin gene polymorphisms and susceptibility to atherosclerosis: A meta-analysis.

Authors:  Marjan Mansourian; Shaghayegh Haghjooy Javanmard
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

5.  Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis.

Authors:  Zixin Cai; Yan Yang; Jingjing Zhang
Journal:  BMC Public Health       Date:  2021-08-04       Impact factor: 3.295

6.  Obesity, adipokines and COVID-19.

Authors:  Adrian Post; Stephan J L Bakker; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2020-06-12       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.